Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma

NCT00079066 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.

NCT NCT00079066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00079066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma
Lead sponsor
NCIC Clinical Trials Group
Phase
Phase 3
Overall status
Completed
Start date
December 30, 2003
Completion date
February 10, 2009
Enrollment
572 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, quality of life